Payment overview · 2025
General Payments
$945.65
11 reported records · 7 companies
Healthcare provider profile · identity verified
Ryan Bradley Estacio Ortizo, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · RIVERSIDE, CA · NPI 1083173348
Verified facts
What the public records show
CMS Open Payments records show Ryan Bradley Estacio Ortizo, M.D. received $945.65 in general payments during 2025 across 11 reported records.
AstraZeneca Pharmaceuticals LP accounted for 42.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Kerendia.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Farxiga by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Kerendia by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $403.69 | 42.7% | 5 | 2025 |
| Intra-Sana Laboratories | Unresolved — no canonical attribution shown | $124.99 | 13.2% | 1 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $124.99 | 13.2% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $121.91 | 12.9% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $113.78 | 12.0% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $32.61 | 3.5% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $23.68 | 2.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $945.65 | 11 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $140.62 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $139.83 | 2 | 2025 |
Source payment records
|
|||||
| GLYCATE Normalized: glycate |
Drug | Intra-Sana Laboratories | $124.99 | 1 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $124.99 | 1 | 2025 |
Source payment records
|
|||||
| RELTONE 200 MG Normalized: reltone 200 mg |
Drug | Intra-Sana Laboratories | $124.99 | 1 | 2025 |
Source payment records
|
|||||
| RELTONE 400 MG Normalized: reltone 400 mg |
Drug | Intra-Sana Laboratories | $124.99 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $123.24 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $121.91 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $113.78 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $32.61 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $23.68 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 70 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
70 | 16 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
67 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 621 | 222 |
| Amlodipine Besylate | Amlodipine Besylate | 317 | 100 |
| Metformin Hcl | Metformin Hcl | 291 | 96 |
| Lisinopril | Lisinopril | 240 | 77 |
| Gabapentin | Gabapentin | 231 | 69 |
| Losartan Potassium | Losartan Potassium | 208 | 75 |
| Tamsulosin Hcl | Tamsulosin Hcl | 184 | 60 |
| Levothyroxine Sodium | Levothyroxine Sodium | 176 | 58 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 148 | 44 |
| Hydrochlorothiazide | Hydrochlorothiazide | 139 | 48 |
| Metoprolol Succinate | Metoprolol Succinate | 137 | 41 |
| Omeprazole | Omeprazole | 132 | 51 |
| Famotidine | Famotidine | 121 | 48 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 116 | 21 |
| Ibuprofen | Ibuprofen | 112 | 43 |
| Pioglitazone Hcl | Pioglitazone Hcl | 111 | 31 |
| Glipizide | Glipizide | 104 | 36 |
| Simvastatin | Simvastatin | 101 | 34 |
| Finasteride | Finasteride | 97 | 35 |
| Furosemide | Furosemide | 97 | 42 |
| Allopurinol | Allopurinol | 92 | 24 |
| Ozempic | Semaglutide | 90 | 16 |
| Metoprolol Tartrate | Metoprolol Tartrate | 86 | 33 |
| Pantoprazole Sodium | Pantoprazole Sodium | 86 | 32 |
| Glipizide Er | Glipizide | 85 | 25 |
| Eliquis | Apixaban | 83 | 15 |
| Alendronate Sodium | Alendronate Sodium | 82 | 35 |
| Fluticasone Propionate | Fluticasone Propionate | 78 | 39 |
| Duloxetine Hcl | Duloxetine Hcl | 77 | 26 |
| Farxiga | Dapagliflozin Propanediol | 70 | 16 |
| Atenolol | Atenolol | 68 | 23 |
| Jardiance | Empagliflozin | 67 | 20 |
| Trazodone Hcl | Trazodone Hcl | 63 | 25 |
| Citalopram Hbr | Citalopram Hydrobromide | 59 | 21 |
| Ezetimibe | Ezetimibe | 57 | 13 |
| Lovastatin | Lovastatin | 56 | 15 |
| Tizanidine Hcl | Tizanidine Hcl | 56 | 13 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 55 | 22 |
| Carvedilol | Carvedilol | 53 | 20 |
| Metformin Hcl Er | Metformin Hcl | 49 | 21 |
| Benazepril Hcl | Benazepril Hcl | 48 | 15 |
| Nifedipine Er | Nifedipine | 47 | 14 |
| Sertraline Hcl | Sertraline Hcl | 47 | 18 |
| Meloxicam | Meloxicam | 46 | 20 |
| Pravastatin Sodium | Pravastatin Sodium | 43 | 17 |
| Fenofibrate | Fenofibrate Nanocrystallized | 41 | 13 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 41 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 41 | 15 |
| Clopidogrel | Clopidogrel Bisulfate | 40 | 17 |
| Irbesartan | Irbesartan | 40 | suppressed |
| Potassium Chloride | Potassium Chloride | 40 | 19 |
| Quetiapine Fumarate | Quetiapine Fumarate | 40 | 18 |
| Trulicity | Dulaglutide | 40 | suppressed |
| Baclofen | Baclofen | 39 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 39 | 14 |
| Donepezil Hcl | Donepezil Hcl | 34 | 15 |
| Enalapril Maleate | Enalapril Maleate | 34 | 11 |
| Mirtazapine | Mirtazapine | 34 | 11 |
| Methocarbamol | Methocarbamol | 33 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 32 | 14 |
| Spironolactone | Spironolactone | 32 | 14 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 32 | 26 |
| Levemir Flexpen | Insulin Detemir | 31 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 31 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 31 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 30 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 30 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 29 | 22 |
| Kerendia | Finerenone | 29 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 29 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 28 | suppressed |
| Xarelto | Rivaroxaban | 28 | suppressed |
| Valsartan | Valsartan | 26 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 25 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 25 | suppressed |
| Aripiprazole | Aripiprazole | 24 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 24 | suppressed |
| Methylprednisolone | Methylprednisolone | 23 | 21 |
| Naproxen | Naproxen | 23 | 12 |
| Oxycodone Hcl | Oxycodone Hcl | 23 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 22 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 22 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 22 | suppressed |
| Alprazolam | Alprazolam | 21 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 21 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 20 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 20 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 19 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 18 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 18 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 17 | 16 |
| Januvia | Sitagliptin Phosphate | 17 | suppressed |
| Lorazepam | Lorazepam | 17 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 16 | suppressed |
| Ciclopirox | Ciclopirox | 16 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 16 | 11 |
| Hydralazine Hcl | Hydralazine Hcl | 16 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 16 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 16 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 16 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 16 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 15 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 15 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 15 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 14 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 14 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 14 | suppressed |
| Sucralfate | Sucralfate | 14 | 12 |
| Tadalafil | Tadalafil | 14 | suppressed |
| Testosterone | Testosterone | 14 | suppressed |
| Topiramate | Topiramate | 14 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 13 | suppressed |
| Glimepiride | Glimepiride | 13 | suppressed |
| Ibu | Ibuprofen | 13 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 13 | suppressed |
| Primidone | Primidone | 13 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 13 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 13 | suppressed |
| Humulin R U-500 Kwikpen | Insulin Regular, Human | 12 | suppressed |
| Hydrocortisone | Hydrocortisone | 12 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Pregabalin | Pregabalin | 12 | suppressed |
| Tradjenta | Linagliptin | 12 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 12 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 12 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 11 | suppressed |
| Ulticare Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $945.65 · 11 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, FARXIGA, GLYCATE, GVOKE HYPOPEN, JOURNAVX, Kerendia, MOUNJARO, RELTONE 200 MG, RELTONE 400 MG, REPATHA | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error